NEW YORK (GenomeWeb News) – Transgenomic yesterday said that it has signed a licensing option agreement with Gene Solutions for a set of validated mutations that can form the basis of a diagnostic test for Parkinson's disease.

Under the agreement, the companies will evaluate the ability of Transgenomic's mitochondrial mutation-detection technology to detect and quantify the presence of the mutations – low-level mitochondrial DNA, or mtDNA, variants that have been shown to be present in Parkinson's disease patients but rarely in age-matched control individuals.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In a series of articles, medical journals debate the necessity of conflict-of-interest policies.

Irwin Rose, who won the 2004 Nobel Prize in Chemistry for his work on ubiquitin-mediated protein degradation, has died.

In Cell this week: biobank of colorectal cancer organoids, ancient wolf genome analysis, and more.

With cloud computing becoming more attractive to researchers, Nature News offers some tips on how to get going.